Literature DB >> 33580042

Innate and secondary humoral responses are improved by increasing the time between MVA vaccine immunizations.

Jean-Louis Palgen1,2, Nicolas Tchitchek1,2, André Rodriguez-Pozo1,2, Quentin Jouhault1,2, Hadjer Abdelhouahab1,2, Nathalie Dereuddre-Bosquet1,2, Vanessa Contreras1,2, Frédéric Martinon1,2, Antonio Cosma1,2, Yves Lévy2,3, Roger Le Grand1,2, Anne-Sophie Beignon4,5.   

Abstract

Comprehending the mechanisms behind the impact of vaccine regimens on immunity is critical for improving vaccines. Indeed, the time-interval between immunizations may influence B and T cells, as well as innate responses. We compared two vaccine schedules using cynomolgus macaques immunized with an attenuated vaccinia virus. Two subcutaneous injections 2 weeks apart led to an impaired secondary antibody response and similar innate myeloid responses to both immunizations. In contrast, a delayed boost (2 months) improved the quality of the antibody response and involved more activated/mature innate cells, induced late after the prime and responding to the recall. The magnitude and quality of the secondary antibody response correlated with the abundance of these neutrophils, monocytes, and dendritic cells that were modified phenotypically and enriched prior to revaccination at 2 months, but not 2 weeks. These late phenotypic modifications were associated with an enhanced ex vivo cytokine production (including IL-12/23 and IL-1β) by PBMCs short after the second immunization, linking phenotype and functions. This integrated analysis reveals a deep impact of the timing between immunizations, and highlights the importance of early but also late innate responses involving phenotypical changes, in shaping humoral immunity.

Year:  2020        PMID: 33580042     DOI: 10.1038/s41541-020-0175-8

Source DB:  PubMed          Journal:  NPJ Vaccines        ISSN: 2059-0105            Impact factor:   7.344


  52 in total

Review 1.  The prime-boost strategy: exciting prospects for improved vaccination.

Authors:  I A Ramshaw; A J Ramsay
Journal:  Immunol Today       Date:  2000-04

Review 2.  Jump-starting the immune system: prime-boosting comes of age.

Authors:  David L Woodland
Journal:  Trends Immunol       Date:  2004-02       Impact factor: 16.687

Review 3.  Prime-boost vaccine strategy against viral infections: Mechanisms and benefits.

Authors:  Kimia Kardani; Azam Bolhassani; Sepideh Shahbazi
Journal:  Vaccine       Date:  2015-12-13       Impact factor: 3.641

4.  Systems Analysis of Immunity to Influenza Vaccination across Multiple Years and in Diverse Populations Reveals Shared Molecular Signatures.

Authors:  Helder I Nakaya; Thomas Hagan; Sai S Duraisingham; Eva K Lee; Marcin Kwissa; Nadine Rouphael; Daniela Frasca; Merril Gersten; Aneesh K Mehta; Renaud Gaujoux; Gui-Mei Li; Shakti Gupta; Rafi Ahmed; Mark J Mulligan; Shai Shen-Orr; Bonnie B Blomberg; Shankar Subramaniam; Bali Pulendran
Journal:  Immunity       Date:  2015-12-15       Impact factor: 31.745

Review 5.  The translational value of non-human primates in preclinical research on infection and immunopathology.

Authors:  Bert A 't Hart; Willy M Bogers; Krista G Haanstra; Frank A Verreck; Clemens H Kocken
Journal:  Eur J Pharmacol       Date:  2015-03-23       Impact factor: 4.432

Review 6.  Vaccines, new opportunities for a new society.

Authors:  Rino Rappuoli; Mariagrazia Pizza; Giuseppe Del Giudice; Ennio De Gregorio
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-18       Impact factor: 11.205

7.  Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox.

Authors:  Patricia L Earl; Jeffrey L Americo; Linda S Wyatt; Leigh Anne Eller; J Charles Whitbeck; Gary H Cohen; Roselyn J Eisenberg; Christopher J Hartmann; David L Jackson; David A Kulesh; Mark J Martinez; David M Miller; Eric M Mucker; Joshua D Shamblin; Susan H Zwiers; John W Huggins; Peter B Jahrling; Bernard Moss
Journal:  Nature       Date:  2004-03-11       Impact factor: 49.962

Review 8.  Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development.

Authors:  A Volz; G Sutter
Journal:  Adv Virus Res       Date:  2016-08-01       Impact factor: 9.937

Review 9.  Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?

Authors:  Ingo Drexler; Caroline Staib; Gerd Sutter
Journal:  Curr Opin Biotechnol       Date:  2004-12       Impact factor: 9.740

Review 10.  Recombinant modified vaccinia virus Ankara-based malaria vaccines.

Authors:  Sarah Sebastian; Sarah C Gilbert
Journal:  Expert Rev Vaccines       Date:  2015-10-29       Impact factor: 5.683

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.